Aldose reductase (ALR2) is a target enzyme for the treatment of diabetic complications. Owing to the limited number of currently available drugs for the treatment of diabetic complications, the discovery of new inhibitors of ALR2 that can potentially be optimized as drugs appears highly desirable. In this study, a molecular docking analysis of the structures of more than 127,006 organic compounds contained in the National Cancer Institute database was performed to find and score molecules that are complementary to ALR2. Besides retrieving several carboxylic acid derivatives, which are known to generally inhibit aldose reductase, docking proposed other families of putative inhibitors such as sulfonic acids, nitro-derivatives, sulfonamides and carbonyl derivatives. Twenty-five compounds, chosen as the highest-scoring representatives of each of these families, were tested as aldose reductase inhibitors. Five of them were found to inhibit aldose reductase in the micromolar range. For these active compounds, selectivity with respect to the closely-related aldehyde reductase was determined by measuring the corresponding inhibitory activities. The structures of the complexes between the new lead inhibitors and aldose reductase, here refined with molecular mechanics and molecular dynamics calculations. suggest that new pharmacophoric groups can bind aldose reductase very efficiently. In the case of the family of the nitro-derivative-inhibitors. a class of particularly interesting compounds, a round of optimizations was performed with the synthesis and biological evaluation of a series of derivatives aimed at testing the proposed binding mode and at improving interaction with active site residues. Starting from a hit compound having an IC50 of 42 muM, the most potent compound synthesized showed a 10-fold increase in inhibitory activity and 10-fold selectivity with respect to ALR1, and structure-activity relationships of the designed compounds were in agreement with the proposed mode of binding at the active site.

Discovery of new inhibitors of aldose reductase from molecular docking and database screening / Rastelli, Giulio; Am, Ferrari; Costantino, Luca; Gamberini, Maria Cristina. - In: BIOORGANIC & MEDICINAL CHEMISTRY. - ISSN 0968-0896. - STAMPA. - 10(2002), pp. 1437-1450. [10.1016/S0968-0896(01)00410-2]

Discovery of new inhibitors of aldose reductase from molecular docking and database screening

RASTELLI, Giulio;COSTANTINO, Luca;GAMBERINI, Maria Cristina
2002

Abstract

Aldose reductase (ALR2) is a target enzyme for the treatment of diabetic complications. Owing to the limited number of currently available drugs for the treatment of diabetic complications, the discovery of new inhibitors of ALR2 that can potentially be optimized as drugs appears highly desirable. In this study, a molecular docking analysis of the structures of more than 127,006 organic compounds contained in the National Cancer Institute database was performed to find and score molecules that are complementary to ALR2. Besides retrieving several carboxylic acid derivatives, which are known to generally inhibit aldose reductase, docking proposed other families of putative inhibitors such as sulfonic acids, nitro-derivatives, sulfonamides and carbonyl derivatives. Twenty-five compounds, chosen as the highest-scoring representatives of each of these families, were tested as aldose reductase inhibitors. Five of them were found to inhibit aldose reductase in the micromolar range. For these active compounds, selectivity with respect to the closely-related aldehyde reductase was determined by measuring the corresponding inhibitory activities. The structures of the complexes between the new lead inhibitors and aldose reductase, here refined with molecular mechanics and molecular dynamics calculations. suggest that new pharmacophoric groups can bind aldose reductase very efficiently. In the case of the family of the nitro-derivative-inhibitors. a class of particularly interesting compounds, a round of optimizations was performed with the synthesis and biological evaluation of a series of derivatives aimed at testing the proposed binding mode and at improving interaction with active site residues. Starting from a hit compound having an IC50 of 42 muM, the most potent compound synthesized showed a 10-fold increase in inhibitory activity and 10-fold selectivity with respect to ALR1, and structure-activity relationships of the designed compounds were in agreement with the proposed mode of binding at the active site.
10
1437
1450
Discovery of new inhibitors of aldose reductase from molecular docking and database screening / Rastelli, Giulio; Am, Ferrari; Costantino, Luca; Gamberini, Maria Cristina. - In: BIOORGANIC & MEDICINAL CHEMISTRY. - ISSN 0968-0896. - STAMPA. - 10(2002), pp. 1437-1450. [10.1016/S0968-0896(01)00410-2]
Rastelli, Giulio; Am, Ferrari; Costantino, Luca; Gamberini, Maria Cristina
File in questo prodotto:
File Dimensione Formato  
article_dock_Rastelli.pdf

non disponibili

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 483.08 kB
Formato Adobe PDF
483.08 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/305489
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 55
  • ???jsp.display-item.citation.isi??? 52
social impact